Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. [electronic resource]
Producer: 20160906Description: e104-6 p. digitalISSN:- 1527-7755
- Adult
- Antibodies, Monoclonal -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bone Neoplasms -- drug therapy
- Brain Neoplasms -- secondary
- CTLA-4 Antigen -- antagonists & inhibitors
- Denosumab -- therapeutic use
- Female
- Humans
- Ipilimumab
- Lymphatic Metastasis
- Melanoma -- drug therapy
- Positron-Emission Tomography
- Proto-Oncogene Proteins B-raf -- genetics
- RANK Ligand -- antagonists & inhibitors
- Skin Neoplasms -- drug therapy
- Time Factors
- Treatment Outcome
- Whole Body Imaging -- methods
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
There are no comments on this title.
Log in to your account to post a comment.